mTOR Inhibition for Cancer Therapy: Past, Present and Future
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, a
- PDF / 5,999,881 Bytes
- 300 Pages / 439.43 x 683.15 pts Page_size
- 32 Downloads / 184 Views
Monica Mita Alain Mita Eric K. Rowinsky Editors
123
mTOR Inhibition for Cancer Therapy: Past, Present and Future
Monica Mita • Alain Mita • Eric K. Rowinsky Editors
mTOR Inhibition for Cancer Therapy: Past, Present and Future
Editors Monica Mita Samuel Oschin Comprehensive Cancer Inst Cedars Sinai Medical Center Los Angeles, CA USA
Eric K. Rowinsky Stemline Therapeutics, Inc New York, NY USA
Alain Mita Samuel Oschin Comprehensive Cancer Inst Cedars-Sinai Medical Center Los Angeles, CA USA
ISBN 978-2-8178-0491-0 ISBN 978-2-8178-0492-7 DOI 10.1007/978-2-8178-0492-7
(eBook)
Library of Congress Control Number: 2015955823 Springer Paris Heidelberg New York Dordrecht London © Springer-Verlag France 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Contents
1
Targeting mTOR: A Little Bit of History and a Large Future . . . . . Eric K. Rowinsky
1
2
The PI3K-mTOR Pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hala Elnakat Thomas, Sónia R. Pereira da Veiga, George Thomas, and Sara C. Kozma
19
3
The Evolving Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . Carlyn C. Tan, Robert A. Figlin, and Andrew E. Hendifar
47
4
The Role of mTOR Inhibitors in Breast Cancer. . . . . . . . . . . . . . . . . Philippe G. Aftimos and Martine J. Piccart-Gebhart
67
5
The Role of mTOR Inhibitors in Neuroendocrine Tumors . . . . . . . . . Andrew E. Hendifar, Sandy Liu, and Edward Wolin
93
6
New Indications of mTOR Inhibitors in Rare Tumors. . . . . . . . . . . . Gaurav Shah, Sotirios Stergiopoulos, and David Lebwohl
113
7
The Role of PI3K/AKT/mTOR Inhibitors in the Treatment of Hematological Malignancies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . James Shen and Kevin R. Kelly
8
The Clinical Pharmacology and Toxicity Profile of Rapalogs . . .
Data Loading...
